Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) and Achaogen Inc. (NASDAQ:AKAO) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven Pharmaceutical Holding Company Ltd.	N/A	0.00	240.92M	-5.61	0.00
Achaogen Inc.	8.73M	3.94	186.51M	-3.96	0.00

Table 1 highlights Biohaven Pharmaceutical Holding Company Ltd. and Achaogen Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us the net margins, return on equity and return on assets of both businesses.

	Net Margins	Return on Equity	Return on Assets
Biohaven Pharmaceutical Holding Company Ltd.	0.00%	-201%	-120.6%
Achaogen Inc.	-2,136.43%	-227.2%	-113.1%

Liquidity

Biohaven Pharmaceutical Holding Company Ltd. has a Current Ratio of 12 and a Quick Ratio of 12. Competitively, Achaogen Inc.’s Current Ratio is 2.5 and has 2.5 Quick Ratio. Biohaven Pharmaceutical Holding Company Ltd.’s better ability to pay short and long-term obligations than Achaogen Inc.

Analyst Recommendations

The Ratings and Recommendations for Biohaven Pharmaceutical Holding Company Ltd. and Achaogen Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Biohaven Pharmaceutical Holding Company Ltd.	0	0	0	0.00
Achaogen Inc.	0	6	0	2.00

Competitively Achaogen Inc. has a consensus target price of $2.75, with potential upside of 411.06%.

Institutional & Insider Ownership

The shares of both Biohaven Pharmaceutical Holding Company Ltd. and Achaogen Inc. are owned by institutional investors at 91.4% and 36.2% respectively. Insiders held roughly 1.1% of Biohaven Pharmaceutical Holding Company Ltd.’s shares. Comparatively, insiders own roughly 16.9% of Achaogen Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Biohaven Pharmaceutical Holding Company Ltd.	3.76%	23.81%	50.91%	27.74%	45.51%	27.53%
Achaogen Inc.	-5.41%	-49.38%	-57.77%	-85.3%	-92.67%	-37.85%

For the past year Biohaven Pharmaceutical Holding Company Ltd. had bullish trend while Achaogen Inc. had bearish trend.

Summary

Achaogen Inc. beats Biohaven Pharmaceutical Holding Company Ltd. on 6 of the 10 factors.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. The company also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to to enable patients to receive safe and efficacious doses of plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.